Eli Lilly and Company LLY announced that two phase III studies evaluating its insulin candidate, Ultra Rapid Lispro (URLi), in type I and type II diabetes patients met the primary efficacy endpoint. The company expects to submit regulatory application based on data from these studies to the FDA in 2019.
A potential approval to URLi is likely to further boost the company's portfolio. However, there may be patients currently on Humalog switching to the new drug.
Shares of Eli Lilly have rallied 27.9% year to date, comparing favorably with the industry 's increase of 7.5%.
The phase III studies - PRONTO-T1D and PRONTO-T2D - evaluated URLi in combination with either insulin glargine or insulin degludec in adult patients to demonstrate non-inferiority toLilly's own insulin lispro injection Humalog in reducing blood glucose levels, as measured by reduction in A1C levels from baseline, after 26 weeks. Data showed that both studies met their primary endpoint.
Moreover, URLi demonstrated significant improvement in post-meal glucose control as measured by reduction in glucose excursions at both one and two hours during a meal test. The overall safety and tolerability profile of URLi was similar to Humalog.
URLi is expected to significantly help patients with uncontrolled or high level of blood sugar after a meal offering an opportunity for the candidate to gain market share upon approval.
Lilly has a strong portfolio of diabetic drugs, which includes Trulicity, Humalog and Humulin with blockbuster potential. The company also has Basaglar, Jardiance and Trajenta in its portfolio, which generated total sales of more than $4.5 billion in the first half of 2018.
Nono Nordisk's NVO Novolog is a direct competitor of Humalog and is likely to give competition to URLi, if approved.
Eli Lilly and Company Price
Eli Lilly and Company Price | Eli Lilly and Company Quote
Zacks Rank & Stocks to Consider
Lilly currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks from the same space are Novartis NVS and Roche RHHBY . Both the stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Novartis' earnings per share estimates have increased from $5.15 to $5.17 for 2018 and from $5.47 to $5.55 for 2019 over the past 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters with an average beat of 2.07%. The stock is up 2.9% so far this year.
Roche's earnings per share estimates have moved up from $2.14 to $2.24 for 2018 and from $2.15 to $2.28 for 2019 over the past 60 days.
Best Electric Car Stock? You'll Never Guess It.
Zacks Research has released a report that may shock many investors. One stock stands out as the best way to invest in the surge to electric cars. And it's not the one you may think!
Much like petroleum 150 years ago, lithium battery power is set to shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge. With battery prices plummeting and charging stations set to multiply, revenues that were already at $31 billion in 2016 are expected to blast to over $67 billion by the end of 2022.
See Zacks Best EV Stock Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Novo Nordisk A/S (NVO): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research